Q4 2024 Earnings Call Transcript March 20, 2025 Operator: Hello, and welcome to the Adaptimmune’s Q4 and Full Year 2024 ...

Locke et al. "Long-term survival of patients with advanced/metastatic synovial sarcoma or myxoid/round cell liposarcoma who received afamitresgene autoleucel T-cell receptor T-cell therapy in ...

Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise. The launch is ...

Were you Seen at The third annual Sarcoma Strong Gala on March 1, 2025, in Glen Sanders Mansion in Scotia? Were you Seen at The third annual Sarcoma Strong Gala on March 1, 2025, in Glen Sanders ...